Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...
Early treatment is critical for mucopolysaccharidosis type I (MPS I), justifying its incorporation into newborn screening. Enzyme replacement therapy (ERT) treats MPS I, yet presumptions that ERT ...
Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion Virus-directed ...
Any practitioner who cares for patients with psoriasis should be familiar with and make use of systemic therapies. These medications are clearly indicated for patients who have diffuse disease where ...
Dr. George Sledge answers the question: 'Local versus systemic therapy?' — -- Question: What is the difference between local and systemic therapy? Answer: Local and systemic therapy in essence ...
Breaking News: Trump administration impacts continue to roil the life sciences sector Home » Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo ...
Phoenix-based Marlyn Nutraceuticals, dba Naturally Vitamins, has extended its contract with MUCOS Pharma of Germany giving them exclusive rights to distribute Wobenzym in the US. Wobenzym, which will ...
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected ...
Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy, named WFX-001, being developed for the treatment of Fabry disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback